Jiangsu Vcare and Yangzhou Princechem Acquired Boya Chemical Company
Published Time:
2017-06-15 17:21
Source:
The signing ceremony of Jiangsu Vcare Pharmaceutical Technology Co., Ltd. and Yangzhou Princechem Co., Ltd. acquiring Boya Chemical (Nantong) Co., Ltd. was held in the conference room of Jiangsu Vcare recently. Boya Chemical (Nantong) Co., Ltd. is located in Yangkou Chemical Industrial Park, Rudong Coastal Economic Development Zone, Jiangsu Province. The company covers an area of 70 acres and is a Hong Kong-owned enterprise.
The goal of this acquisition is to build Boya Chemical into a raw material drug manufacturer that meets the standards of China, the United States and the European Union. After renovation, Boya Chemical will be a chemical raw materials production base of Yatai Group and solve the bottleneck problem of Vcare's raw material drug R&D and production. It’s believed that the acquisition will make a significant contribution to Vcare’s production and sales of intermediates and APIs.
江苏威凯尔总经理刘永强与博雅化学董事长木村理绘在签字仪式上
Related News
11
2025
/
08
August 8, 2025 – Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced today that it has entered into an exclusive strategic partnership with Huadong Medicine (Hangzhou) Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (000963.SZ, "Huadong Medicine"), for the commercialization rights of Jiangsu Vcare’s innovative product VC005 tablets in mainland China.
View Details
31
2025
/
07
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the completion of full patient enrollment for its Phase II clinical trial of the self-developed, next-generation highly selective JAK1 inhibitor, VC005 topical gel, for the treatment of mild-to-moderate Atopic Dermatitis (AD). This marks a significant milestone in the VC005 gel development program.
View Details
03
2025
/
07
Recently, the NDA for Eratrectinib (VC004) capsules, a next-generation anti-resistance TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) has been officially accepted by China's NMPA. Previously granted priority review designation, the drug holds promise as a new treatment option for patients with advanced solid tumors.
View Details
30
2025
/
05
Recently, Eratrectinib (VC004) capsules, a self-developed next-generation anti-resistant TRK inhibitor by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), were included in the priority review list by the NMPA, through public notice. This milestone positions the drug within the first tier of next-generation anti-resistant products targeting the same mechanism in China.
View Details
21
2025
/
05
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the completion of patient enrollment for its self-developed Class 1 innovative antiplatelet drug, Vicagrel Capsules, in a Phase III clinical trial conducted in China. This study evaluates the efficacy and safety of Vicagrel compared to Clopidogrel in patients with acute coronary syndrome (ACS). The milestone marks a critical step toward Vicagrel’s potential market approval.
View Details
09
2025
/
05
On May 8, 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) achieved another major milestone in its self-developed second-generation highly selective JAK1 inhibitor, VC005 tablets. The project, intended for the oral treatment of non-segmental vitiligo received official IND approval from the NMPA (Application No.: CXHL2500200).
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn